NCT06418165Recruiting
Vienna Hypothermic Oxygenated Machine Perfusion Study
Vienna Hypothermic Oxygenated Machine Perfusion for Liver Transplantation Study
Source: ClinicalTrials.gov · Last updated 17 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this observational cohort study data on all patients undergoing liver transplantation after hypothermic oxygenated machine perfusion at Medical University of Vienna will be prospectively recorded. Investigation of short- and long-term outcome in this cohort will be conducted.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 10 May 2024
- Start date
- 1 Jan 2018
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Medical University of Vienna
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06418165
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jan 2018 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- pregnancy
- partial grafts
- the anatomical integrity of the liver is not preserved in a way that makes the perfusion of the liver possible
Who the study is looking for
- patients undergoing liver transplantation with the use of hypothermic oxygenated machine perfusion
- age ≥ 18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Vienna Coordinator of this site? Confirm its status | Vienna | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.